Aryl sulfonamides as blt1 antagonists

Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B 4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B 4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

1 . A compound of structural formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
         A is selected from the group consisting of:
 (1) aryl, and 
 (2) heteroaryl, 
 
         wherein aryl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen; 
         B is selected from the group consisting of:
 (1) aryl, and 
 (2) heteroaryl, 
 
         wherein aryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, halogen and CF 3 , and wherein heteroaryl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 ; 
         X is selected from the group consisting of:
 (1) —NHSO 2 CF 3 , 
 (2) —NHSO 2 CH 2 CF 3 , 
 (3) —NHSO 2 CHF 2 , 
 (4) —NHSO 2 C 1-6 alkyl, 
 (5) —NHSO 2 CH 2 C 3-6 cycloalkyl, and 
 (6) —NHSO 2 C 3-6 cycloalkyl, 
 
         wherein alkyl and cycloalkyl are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl; 
         Z is selected from the group consisting of:
 (1) hydrogen, 
 (2) C 1-6 alkyl, and 
 (3) phenyl, 
 
         wherein alkyl and phenyl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl; 
         R a  is selected from the group consisting of:
 (1) hydrogen, 
 (2) halogen, and 
 (3) C 1-6 alkyl; and 
 
         R b  is selected from the group consisting of:
 (1) hydrogen, 
 (2) halogen, and 
 (3) C 1-6 alkyl. 
 
       
     
     
         2 . The compound according to  claim 1  wherein Z is hydrogen or —C 1-6 alkyl; or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The compound according to  claim 1  wherein Z is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl; or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The compound according to  claim 1  wherein X is selected from the group consisting of:
 (1) —NHSO 2 CF 3 , 
 (2) —NHSO 2 CH 2 CF 3 , 
 (3) —NHSO 2 CHF 2 , 
 (4) —NHSO 2 C 1-6 alkyl, and 
 (5) —NHSO 2 C 3-6 cycloalkyl, 
 
       wherein alkyl and cycloalkyl are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl; or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The compound according to  claim 1  wherein X is —NHSO 2 CF 3 ; or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The compound according to  claim 1  wherein A is selected from the group consisting of:
 (1) phenyl, and 
 (2) heteroaryl, 
 
       wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen; or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The compound according to  claim 1  wherein A is phenyl, wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl and halogen; or a pharmaceutically acceptable salt thereof. 
     
     
         8 . The compound according to  claim 1  wherein A is heteroaryl, wherein heteroaryl is unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl and halogen; or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The compound according to  claim 1  wherein A is selected from the group consisting of:
 (1) pyrazole, 
 (2) pyridine, 
 (3) thiophene, 
 (4) thiazole, 
 (5) benzothiophene, 
 (6) triazole, 
 (7) oxazole, 
 (8) pyrazine, 
 (9) thiadiazole, and 
 (10) pyridazine, 
 
       wherein pyrazole, pyridine, thiophene, thiazole, benzothiophene, triazole, oxazole, pyrazine, thiadiazole, and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen; or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The compound according to  claim 1  wherein A is pyridine; or a pharmaceutically acceptable salt thereof. 
     
     
         11 . The compound according to  claim 1  wherein B is selected from the group consisting of:
 (1) phenyl, 
 (2) pyrazine, 
 (3) pyridine, and 
 (4) pyridazine, 
 
       wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, halogen and CF 3 , and wherein pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 ; or a pharmaceutically acceptable salt thereof. 
     
     
         12 . The compound according to  claim 1  wherein B is phenyl; or a pharmaceutically acceptable salt thereof. 
     
     
         13 . The compound according to  claim 1  wherein B is pyridine, wherein pyridine is unsubstituted or substituted with 1-3 substituents independently selected from halogen; or a pharmaceutically acceptable salt thereof. 
     
     
         14 . The compound according to  claim 1  wherein R a  and R b  are independently selected from the group consisting of: hydrogen, and C 1-6 alkyl; or a pharmaceutically acceptable salt thereof. 
     
     
         15 . The compound according to  claim 1  wherein R a  and R b  are hydrogen; or a pharmaceutically acceptable salt thereof. 
     
     
         16 . The compound according to  claim 1  wherein
 A is selected from the group consisting of:
 (1) phenyl, and 
 (2) heteroaryl, 
 
 wherein phenyl and heteroaryl are unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl, C 3-6 cycloalkyl, and halogen; 
 B is selected from the group consisting of:
 (1) phenyl, 
 (2) pyrazine, 
 (3) pyridine, and 
 (4) pyridazine, 
 
 wherein pyrazine, pyridine and pyridazine are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl, halogen, and CF 3 ; 
 X is selected from the group consisting of:
 (1) —NHSO 2 CF 3 , 
 (2) —NHSO 2 CH 2 CF 3 , 
 (3) —NHSO 2 CHF 2 , 
 (4) —NHSO 2 C 1-6 alkyl, and 
 (5) —NHSO 2 C 3-6 cycloalkyl, 
 
 wherein alkyl and cycloalkyl are unsubstituted or substituted with 1-3 substituents independently selected from C 1-6 alkyl; 
 Z is selected from the group consisting of:
 (1) hydrogen, and 
 (2) phenyl, 
 
 wherein phenyl is unsubstituted or substituted with 1-4 substituents independently selected from C 1-6 alkyl; and 
 R a  and R b  are independently selected from the group consisting of: hydrogen, and C 1-6 alkyl; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
         17 . The compound according to  claim 1  wherein
 A is heteroaryl; 
 B is phenyl; 
 X is —NHSO 2 CF 3 ; 
 Z is hydrogen; and 
 R a  and R b  are hydrogen; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
         18 . The compound according to  claim 21  selected from:
 (1) N-(2-((3,4-Rac-cis)-3-benzyl-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (2) N-(2-((3,4-Rac-trans)-3-benzyl-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (3) N-(2-((3,4-Rac-cis)-3-([1,1′-biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (4) N-(2-((3,4-Rac-trans)-3-([1,1′-biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (5) 1,1,1-Trifluoro-N-(2-((3,4-rac-trans)-4-hydroxy-3-((5-phenylthiophen-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (6) N-(2-((3,4-Rac-trans)-3-((1H-pyrazol-3-yl)methyl)-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (7) 1,1,1-Trifluoro-N-(2-((3,4-rac-trans)-4-hydroxy-3-(pyridin-3-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (8) 1,1,1-Trifluoro-N-(2-((3,4-rac-trans)-4-hydroxy-3-(thiophen-3-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (9) 1,1,1-Trifluoro-N-(2-((3,4-rac-trans)-4-hydroxy-3-(thiazol-5-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (10) 1,1,1-Trifluoro-N-(2-((3,4-rac-cis)-4-hydroxy-3-(thiazol-5-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (11) 1,1,1-Trifluoro-N-(2-((3,4-rac-trans)-4-hydroxy-3-((5-methylpyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (12) N-(2-((3,4-Rac-trans)-3-((1H-pyrazol-4-yl)methyl)-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (13) 1,1,1-Trifluoro-N-(2-((3,4-rac-trans)-4-hydroxy-3-((1-methyl-1H-pyrazol-5-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (14) 1,1,1-Trifluoro-N-(2-{(rac-trans)-4-hydroxy-3-[(1-phenyl-1H-1,2,3-triazol-4-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (15) 1,1,1-Trifluoro-N-{2-[(rac-trans)-4-hydroxy-3-(1,3-oxazol-2-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; 
 (16) 1,1,1-Trifluoro-N-(2-{(rac-trans)-4-hydroxy-3-[(2-methyl-1,3-thiazol-4-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (17) N-(2-{(rac-trans)-3-[(2-cyclopropyl-1,3-thiazol-4-yl)methyl]-4-hydroxy-3,4-dihydro-2H-chromen-7-yl}phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (18) 1,1,1-Trifluoro-N-(2-{(rac-trans)-4-hydroxy-3-[(1-methyl-1H-pyrazol-3-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (19) 1,1,1-Trifluoro-N-(2-{(rac-trans)-3-[(3-fluoropyridin-2-yl)methyl]-4-hydroxy-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (20) 1,1,1-Trifluoro-N-(2-{(rac-trans)-4-hydroxy-3-[(6-methylpyridin-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (21) 1,1,1-Trifluoro-N-(2-{(rac-trans)-4-hydroxy-3-[(3-methylpyridin-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (22) 1,1,1-Trifluoro-N-(2-{(rac-trans)-4-hydroxy-3-[(5-methyl-1,3-thiazol-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (23) 1,1,1-Trifluoro-N-(2-{(rac-trans)-4-hydroxy-3-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (24) 1,1,1-Trifluoro-N-(2-((rac-trans)-4-hydroxy-3-((2-phenylthiazol-4-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (25) 1,1,1-trifluoro-N-{2-[(3R,4S)-4-hydroxy-3-(pyridin-4-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; 
 (26) 1,1,1-trifluoro-N-{2-[(3 S,4R)-4-hydroxy-3-(pyridin-4-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; 
 (27) 1,1,1-Trifluoro-N-{2-[(rac-trans)-4-hydroxy-3-(pyrazin-2-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; 
 (28) 1,1,1-Trifluoro-N-{2-[(rac-trans)-4-hydroxy-3-(pyridazin-3-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methane-sulfonamide; 
 (29) 1,1,1-Trifluoro-N-(2-((rac-trans)-3-((5-fluoropyridin-2-yl)methyl)-4-hydroxychroman-7-yl)phenyl)methanesulfonamide; 
 (30) N-(2-((3,4-Rac-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (31) 1,1,1-trifluoro-N-(2-(3,4-rac-cis)-4-hydroxy-3-(thiazol-4-ylmethyl)chroman-7-yl)phenyl)metha-nesulfonamide; 
 (32) 1,1,1-trifluoro-N-(2-((3,4-rac-trans)-4-hydroxy-3-(thiazol-4-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (33) 1,1,1-Trifluoro-N-(2-((3,4-rac-trans)-4-hydroxy-3-(thiophen-2-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (34) N-(2-((3,4-rac-trans)-3-(benzo[b]thiophen-2-ylmethyl)-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (35) 1,1,1-Trifluoro-N-(2-((rac-trans)-4-hydroxy-3-((1-methyl-3-phenyl-1H-pyrazol-5-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (36) 1,1,1-Trifluoro-N-(2-((3S,4R)-4-hydroxy-3-((1-methyl-3-phenyl-1H-pyrazol-5-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (37) 1,1,1-Trifluoro-N-(2-((3R,4S)-4-hydroxy-3-((1-methyl-3-phenyl-1H-pyrazol-5-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (38) 1,1,1-Trifluoro-N-(2-((rac-trans)-4-hydroxy-3-((5-phenylpyridin-2-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (39) (2-((3S,4R)-4-hydroxy-3-((5-phenylpyridin-2-yl)methyl)chroman-7-yl)phenyl)((trifluoromethyl)sulfonyl)amide; 
 (40) (2-((3R,4S)-4-hydroxy-3-((5-phenylpyridin-2-yl)methyl)chroman-7-yl)phenyl)((trifluoromethyl)sulfonyl)amide; 
 (41) 1,1,1-Trifluoro-N-(2-((rac-trans)-4-hydroxy-3-((2-phenylthiazol-5-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (42) 1,1,1-Trifluoro-N-(2-((3S,4R)-4-hydroxy-3-((2-phenylthiazol-5-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (43) 1,1,1-Trifluoro-N-(2-((3R,4S)-4-hydroxy-3-((2-phenylthiazol-5-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (44) 1,1,1-Trifluoro-N-(2-((3,4-trans)-3-((5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl)methyl)-4-hydroxychroman-7-yl)phenyl)methanesulfonamide; 
 (45) N-(2-((3,4-trans)-3-((2-(tert-butyl)thiazol-4-yl)methyl)-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (46) N-(2-((3S,4R)-3-((1-ethyl-1H-pyrazol-3-yl)methyl)-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (47) N-(2-((3R,4S)-3-((1-ethyl-1H-pyrazol-3-yl)methyl)-4-hydroxychroman-7-yl)phenyl)-1,1,1-trifluoromethanesulfonamide; 
 (48) 1,1,1-Trifluoro-N-(2-((rac-trans)-4-hydroxy-3-((1-phenyl-1H-pyrazol-5-yl)methyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (49) (2-((3,4-trans)-4-hydroxy-3-((1-phenyl-1H-pyrazol-5-yl)methyl)chroman-7-yl)phenyl)((trifluoromethyl)sulfonyl)amide; 
 (50) 1,1,1-trifluoro-N-{2-[(3R,4S)-4-hydroxy-3-(1,3-thiazol-4-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}-methanesulfonamide; 
 (51) 1,1,1-trifluoro-N-{2-[(3S,4R)-4-hydroxy-3-(1,3-thiazol-4-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}-methanesulfonamide; 
 (52) 1,1,1-trifluoro-N-(2-{(3S,4R)-4-hydroxy-3-[(5-methyl-1,3-thiazol-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (53) 1,1,1-trifluoro-N-(2-{(3R,4S)-4-hydroxy-3-[(5-methyl-1,3-thiazol-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (54) 1,1,1-trifluoro-N-{2-[(3 S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}-methanesulfonamide; 
 (55) 1,1,1-trifluoro-N-{2-[(3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}-methanesulfonamide; 
 (56) 1,1,1-Trifluoro-N-(2-{(3R,4S)-4-hydroxy-3-[(2-methyl-1,3-thiazol-4-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)-methanesulfonamide; 
 (57) 1,1,1-Trifluoro-N-(2-{(3S,4R)-4-hydroxy-3-[(2-methyl-1,3-thiazol-4-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)-methanesulfonamide; 
 (58) N-{2-[(3R,4S)-3-benzyl-4-hydroxy-3,4-dihydro-2H-chromen-7-yl]phenyl}-1,1,1-trifluoromethanesulfonamide; 
 (59) N-{2-[(3S,4R)-3-benzyl-4-hydroxy-3,4-dihydro-2H-chromen-7-yl]phenyl}-1,1,1-trifluoromethanesulfonamide; 
 (60) 1,1,1-Trifluoro-N-(2-{(3,4-trans)-4-hydroxy-3-[(3-methylpyridin-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (61) 1,1,1-trifluoro-N-{2-[(3R,4S)-4-hydroxy-3-(thiophen-2-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; 
 (62) 1,1,1-trifluoro-N-{2-[(3 S,4R)-4-hydroxy-3-(thiophen-2-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; 
 (63) 1,1,1-Trifluoro-N-(2-{(3,4-trans)-4-hydroxy-3-[(6-methyl-pyridin-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl}-phenyl)methanesulfonamide; 
 (64) 1,1,1-Trifluoro-N-(2-((3R,4S)-4-hydroxy-3-((2-phenylthiazol-4-yl)-methyl)chroman-7-yl)-phenyl)methanesulfonamide; 
 (65) 1,1,1,-Trifluoro-N-(2-((3S,4R)-4-hydroxy-3-((2-phenylthiazol-4-yl)-methyl)chroman-7-yl)-phenyl)methanesulfonamide; 
 (66) 1,1,1-trifluoro-N-(2-{(3,4-trans)-4-hydroxy-3-[(1-methyl-1H-pyrazol-5-yl)methyl]-3,4-di-hydro-2H-chromen-7-yl}-phenyl)methanesulfonamide; 
 (67) N-{2-[(3S,4R)-3-(biphenyl-4-ylmethyl)-4-hydroxy-3,4-dihydro-2H-chromen-7-yl]phenyl}- 1 , 1 , 1 -trifluoromethanesulfonamide; 
 (68) N-{2-[(3R,4S)-3-(biphenyl-4-ylmethyl)-4-hydroxy-3,4-dihydro-2H-chromen-7-yl]phenyl}- 1 , 1 , 1 -trifluoromethanesulfonamide; 
 (69) 1,1,1-Trifluoro-N-(2-{(3,4-trans)-3-[(3-fluoropyridin-2-yl)methyl]-4-hydroxy-3,4-dihydro-2H-chromen-7-yl}phenyl)methanesulfonamide; 
 (70) 1,1,1-Trifluoro-N-(2-{(3,4-trans)-4-hydroxy-3-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-3,4-dihydro-2H-chromen-7-yl)}phenyl)-methanesulfonamide; 
 (71) 1,1,1-trifluoro-N-{2-[(3,4-trans)-4-hydroxy-3-(1H-pyrazol-3-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}-methanesulfonamide; 
 (72) N-{2-[(3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; 
 (73) N-{2-[(3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)-3,4-dihydro-2H-chromen-7-yl]phenyl}methanesulfonamide; 
 (74) 1,1,1-Trifluoro-N-(3-((3,4-rac-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyrazin-2-yl)methanesulfonamide; 
 (75) N-(2-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)phenyl)-1-methylcyclopropane-1-sulfonamide; 
 (76) 2,2,2-Trifluoro-N-(3-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyrazin-2-yl)ethanesulfonamide; 
 (77) 2,2,2-Trifluoro-N-(3-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridin-2-yl)ethanesulfonamide; 
 (78) 2,2,2-Trifluoro-N-(3-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridin-2-yl)ethanesulfonamide; 
 (79) 2,2,2-Trifluoro-N-(2-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)phenyl)ethanesulfonamide; 
 (80) 2,2,2-Trifluoro-N-(2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)phenyl)ethanesulfonamide; 
 (81) 1,1-Difluoro-N-(2-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (82) 1,1-Difluoro-N-(2-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (83) 1,1,1-Trifluoro-N-(4-fluoro-2-((3,4-trans)-4-hy droxy-3-(pyridin-2-ylmethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 (84) 1,1,1-Trifluoro-N-(5-fluoro-3-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridin-2-yl)methanesulfonamide; 
 (85) 1,1,1-Trifluoro-N-(5-fluoro-3-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridin-2-yl)methanesulfonamide; 
 (86) 1,1-Difluoro-N-(3-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridin-2-yl)methanesulfonamide; 
 (87) 1,1,1-Trifluoro-N-(3-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridin-2-yl)methanesulfonamide; 
 (88) 2,2,2-Trifluoro-N-(3-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)-5-(trifluoromethyl)pyrazin-2-yl)ethanesulfonamide; 
 (89) N-(6-chloro-4-((3R,4S)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridazin-3-yl)-1,1,1-trifluoromethanesulfonamide; 
 (90) N-(4-((3,4-trans)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridazin-3-yl)-1,1,1-trifluoro-methanesulfonamide; 
 (91) N-(6-chloro-4-((3S,4R)-4-hydroxy-3-(pyridin-2-ylmethyl)chroman-7-yl)pyridazin-3-yl)-1,1,1-trifluoromethanesulfonamide; 
 (92) 1,1,1-Trifluoro-N-(2-((3R,4S)-4-hydroxy-3-(1-(2-phenylthiazol-4-yl)ethyl)chroman-7-yl)phenyl)methanesulfonamide; and 
 (93) 1,1,1-trifluoro-N-(4-fluoro-2-(4-hydroxy-3-(1-(pyridin-2-yl)ethyl)chroman-7-yl)phenyl)methanesulfonamide; 
 or a pharmaceutically acceptable salt thereof. 
 
     
     
         19 . A pharmaceutical composition comprising a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . A method of treating or preventing a disorder, condition or disease that may be responsive to the antagonism of the BLT1 receptor in a patient in need thereof comprising administration of a therapeutically effective amount of a compound according to  claim 1 . 
     
     
         23 . A method of treating type 2 diabetes mellitus in a patient in need of treatment comprising the administration to the patient of a therapeutically effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof.